---
layout: post
title: "三生国健：SSGJ-617注射液临床试验获批"
date: 2022-03-22 16:00:02 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.688336" data-code="688336|1|1" data-code2="688336|1|23|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.688336&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 688336_0" data-code="K 688336|1|1" data-code2="K 688336|1|23|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>三生国健公告，公司药品SSGJ-617注射液收到国家药监局核准签发的晚期实体瘤临床试验《药物临床试验批准通知书》。<br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203222318875638>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)